7.

- Nuevos Marcadores de Cncer

Pancretico

Bibliografa
Ballehaninna, U. and Chamberlain, R. (2013). Biomarkers for pancreatic cancer: promising
new markers and options beyond CA 19-9.Tumor Biol., 34(6), pp.3279-3292.
Bauden, M., Pamart, D., Ansari, D., Herzog, M., Eccleston, M., Micallef, J., Andersson, B.
and Andersson, R. (2015). Circulating nucleosomes as epigenetic biomarkers in pancreatic
cancer.Clinical Epigenetics, 7(1).
Honda, K., Kobayashi, M., Okusaka, T., Rinaudo, J., Huang, Y., Marsh, T., Sanada, M.,
Sasajima, Y., Nakamori, S., Shimahara, M., Ueno, T., Tsuchida, A., Sata, N., Ioka, T.,
Yasunami, Y., Kosuge, T., Miura, N., Kamita, M., Sakamoto, T., Shoji, H., Jung, G.,
Srivastava, S. and Yamada, T. (2015). Plasma biomarker for detection of early stage
pancreatic cancer and risk factors for pancreatic malignancy using antibodies for
apolipoprotein-AII isoforms.Sci. Rep., 5, p.15921.
Rckert, F., Pilarsky, C. and Grtzmann, R. (2010). Serum Tumor Markers in Pancreatic
CancerRecent Discoveries.Cancers, 2(2), pp.1107-1124.
Zang, W., Wang, Y., Wang, T., Du, Y., Chen, X., Li, M. and Zhao, G. (2015). miR-663
attenuates tumor growth and invasiveness by targeting eEF1A2 in pancreatic
cancer.Molecular Cancer, 14(1), p.37.